Real-World Medication Adherence Trajectories to Nintedanib Among Idiopathic Pulmonary Fibrosis Patients
Latest Information Update: 23 Apr 2024
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 28 Jun 2022 Status changed from not yet recruiting to completed.
- 30 Aug 2021 New trial record